44227 Dortmund, de
+49 (231) 9742-6300
User Meeting "Clinical Applications of Protein Arrays" in Dortmund
Dr. Peter Schulz-Knappe, CSO of Protagen AG stated: "The relevance of autoantibody signatures for advanced diagnostic and therapeutic indications are becoming increasingly important and Protagen is well positioned with it's validated UNIarray® technology to serve the needs in this market segment. More than 70 attendants enjoyed the interdisciplinary atmosphere at the symposium and engaged in network discussions with experts from all relevant disciplines involved in personalized medicine and modern diagnostic assay platforms. A follow-up meeting is already planned for fall 2011.
Background: UNIarray® is a unique technology platform for the development of novel diagnostics based on indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication specific determination of autoantibody patterns will serve as a unique basis to address hitherto unmet diagnostic needs. In addition, UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification tools for clinical studies.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.